---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-25-001030"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:24:56.604745+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lexaria expands GLP-1-H24-4 trial with 5th tirzepatide arm

## Summary
- Added 5th study arm investigating DehydraTECH-tirzepatide capsules in GLP1-H24-4 diabetes trial.
- Existing four arms increased from 20 to 24 subjects; new arm will recruit 24 subjects.
- Change Order with Novotech adds ~AU$1,900,000 to approved budget.
- Human research ethics committee approval for the new arm was granted Feb 24, 2025.
- Study evaluates DehydraTECH delivery of cannabidiol and GLP-1 agonists in pre/Type II diabetes.

## SEC filing metadata
- accession: 0001640334-25-001030
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.0
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033425001030/0001640334-25-001030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033425001030/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-25-001030
- JSON: https://secwatch.observer/filing/0001640334-25-001030.json
- Plain text: https://secwatch.observer/filing/0001640334-25-001030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.